Menu

Japanese Authorities Recommend Not Regulating Gene Editing

Unlike judges in the European Union, a government panel in Japan says transgenic modification and genome editing are not the same.

Aug 22, 2018
Kerry Grens

ABOVE: © ISTOCK, VISUALSPACE

A Japanese government panel announced Monday (August 20) that it recommends regulating only genetically modified organisms that have had foreign genes permanently introduced into their genomes and not those whose endogenous genes have been edited, according to NHK World-Japan. This means that developers will not have to get approval from the government to produce gene-edited organisms, The Mainichi reports.

The only stipulation is that researchers and businesses will have to register their modifications to plants or animals with the government, with the exception of microbes cultured in contained environments. “We judged that there needed to be some kind of management system in place to earn consumers’ trust,” a panel member tells The Mainichi.

See “The Unregulation of Biotech Crops

Reactions to the decision are mixed. A representative from the Japan Bioindustry Association expressed support to NHK for the recommendation. While lauding the potential benefits of genome editing, an editorial in The Asahi Shimbun opposes across-the-board permission. “Since it is a new technique, there is no ruling out unforeseen risks in gene editing,” it reads. “There have actually been reports on unintended mutations as a result of gene editing.”

The newspaper recommends following the lead of the European Court of Justice, which last month decided that genetically modified products must go through the same safety and labeling processes regardless of method.

See “No Regulatory Exemption for Gene-Edited Products in EU

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.